- Home
- ABOS vs CRVS Comparison
ABOS vs CRVS Comparison
Compare ABOS & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABOS
- CRVS
- Stock Information
- Founded
- ABOS 1996
- CRVS 2014
- Country
- ABOS United States
- CRVS United States
- Employees
- ABOS N/A
- CRVS N/A
- Industry
- ABOS Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- ABOS Health Care
- CRVS Health Care
- Exchange
- ABOS Nasdaq
- CRVS Nasdaq
- Market Cap
- ABOS 166.4M
- CRVS 161.4M
- IPO Year
- ABOS 2021
- CRVS 2016
- Fundamental
- Price
- ABOS $2.44
- CRVS $4.39
- Analyst Decision
- ABOS Strong Buy
- CRVS Buy
- Analyst Count
- ABOS 4
- CRVS 3
- Target Price
- ABOS $9.00
- CRVS $5.75
- AVG Volume (30 Days)
- ABOS 184.0K
- CRVS 353.6K
- Earning Date
- ABOS 08-13-2024
- CRVS 08-06-2024
- Dividend Yield
- ABOS N/A
- CRVS N/A
- EPS Growth
- ABOS N/A
- CRVS N/A
- EPS
- ABOS N/A
- CRVS N/A
- Revenue
- ABOS N/A
- CRVS N/A
- Revenue This Year
- ABOS N/A
- CRVS N/A
- Revenue Next Year
- ABOS N/A
- CRVS N/A
- P/E Ratio
- ABOS N/A
- CRVS N/A
- Revenue Growth
- ABOS N/A
- CRVS N/A
- 52 Week Low
- ABOS $1.81
- CRVS $1.05
- 52 Week High
- ABOS $5.76
- CRVS $4.75
- Technical
- Relative Strength Index (RSI)
- ABOS 40.88
- CRVS 60.71
- Support Level
- ABOS $2.15
- CRVS $3.90
- Resistance Level
- ABOS $2.45
- CRVS $4.20
- Average True Range (ATR)
- ABOS 0.16
- CRVS 0.28
- MACD
- ABOS -0.04
- CRVS -0.07
- Stochastic Oscillator
- ABOS 28.99
- CRVS 31.82
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).